P/E spoločnosti SinoMab BioScience
Aká je hodnota metriky P/E spoločnosti SinoMab BioScience?
Hodnota metriky P/E spoločnosti SinoMab BioScience Limited je N/A
Aká je definícia metriky P/E?
P/E ratio je koeficient daný pomerom ceny akcie a príjmu spoločnosti na akciu za posledných 12 mesiacov.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E spoločností v sektore Health Care sektor na HKSE v porovnaní so spoločnosťou SinoMab BioScience
Čomu sa venuje spoločnosť SinoMab BioScience?
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
Firmy s metrikou p/e podobnou spoločnosti SinoMab BioScience
- Hodnota metriky P/E spoločnosti Pivot Pharmaceuticals je N/A
- Hodnota metriky P/E spoločnosti Electrolux AB je N/A
- Hodnota metriky P/E spoločnosti Summit Ascent je N/A
- Hodnota metriky P/E spoločnosti TFG International je N/A
- Hodnota metriky P/E spoločnosti The Bankers Investment Trust Plc je N/A
- Hodnota metriky P/E spoločnosti Buckhaven Capital je N/A
- Hodnota metriky P/E spoločnosti SinoMab BioScience je N/A
- Hodnota metriky P/E spoločnosti Wallix Sa je N/A
- Hodnota metriky P/E spoločnosti Morris je N/A
- Hodnota metriky P/E spoločnosti Whispir Ltd je N/A
- Hodnota metriky P/E spoločnosti Tobii AB (publ) je N/A
- Hodnota metriky P/E spoločnosti Royal BAM Groep NV je N/A
- Hodnota metriky P/E spoločnosti comScore je N/A